Research programme: neuraminidase inhibitors - Vaxart/Daiichi Sankyo
Alternative Names: BTA929; BTA938; BTA978Latest Information Update: 16 Feb 2018
At a glance
- Originator Biota Holdings
- Developer Aviragen Therapeutics; Daiichi Sankyo Company
- Class Guanidines
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Influenza virus infections
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in Australia (Inhalation)
- 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics